Soviet science and the pineal gland
1970s-1980s (research program began 1971; AEDG tetrapeptide isolated/synthesized 1980s; natural presence in pineal extract not confirmed until 2017)
Epitalon was synthesized, patented, and studied for roughly thirty years as a "pineal longevity peptide" before anyone proved its four-amino-acid sequence was actually present in the pineal extract it was designed to mimic — that confirmation didn't arrive until a 2017 mass-spectrometry paper, from the very lab that invented it.
In 1971, a young Soviet military doctor named Vladimir Khavinson walked out of Leningrad's S.M. Kirov Military Medical Academy with a fresh commission and, over the next decade, a string of postings across the Trans-Baikal and Leningrad Military Districts. His remit, as later accounts describe it, was starkly practical: keep soldiers, nuclear-accident responders, and cosmonauts alive against radiation, brutal cold, and the fast-forward aging that chronic operational stress inflicts on the body.
Khavinson's fix was startlingly reductionist for the era. Harvest crude polypeptide complexes from specific organs — thymus, pineal gland, brain cortex, retina, blood vessels — then reinject them, betting that each organ's own short peptide 'bioregulators' could coax an aged tissue back toward its younger self. The pineal extract, drawn from bovine glands, was named Epithalamin, and by the 1970s and '80s his group — later the St. Petersburg Institute of Bioregulation and Gerontology, which he directed until his death in January 2024 — was testing it in mice, rats, and elderly rhesus monkeys, where it restored a more youthful nighttime melatonin peak and reset age-drifted cortisol and blood-sugar rhythms.
Then came the genuinely clever move. In the 1980s, hunting for the smallest active piece of that messy extract, Khavinson's chemists synthesized a candidate just four amino acids long — alanine-glutamate-aspartate-glycine, or AEDG — and christened it Epitalon. For the next three decades it was studied as though it were the extract's beating heart: lifespan trials in mice and rats, tumor-incidence studies in cancer-prone rodents, and a long human observational study (Khavinson & Morozov, 2003) that followed 266 elderly patients for 6–8 years. The catch? Nobody had shown AEDG was actually in the real pineal extract — it was an inspired guess, not an isolated natural product — and the proof didn't land until a 2017 mass-spectrometry paper from Khavinson's own lab finally found the sequence sitting there all along.
So how well does it hold up? The 2003 study reported striking mortality drops — roughly 2-fold with the thymic peptide alone, about 2.5-fold with the combined pineal-plus-thymic treatment, and up to 4.1-fold with repeated annual courses over six years — but it was a single-institution, open-label observational study, not a randomized trial. And nearly the whole evidence base traces to Khavinson's institute and a tight circle of collaborators (Vladimir Anisimov's oncology group in St. Petersburg, the Korkushko-Shatilo team at Kyiv's Institute of Gerontology), with essentially no independent Western replication of the headline lifespan and mortality claims.
The heart of the story checks out — the roughly 30-year gap and that 2017 confirmation paper (Khavinson et al., Bull Exp Biol Med, PMID 29124531) are real — but a few edges are polished: the widely repeated "Kremlin orders" and cosmonaut-program backstory traces to peptide-vendor marketing rather than documented history, and the famous mortality numbers come from a single open-label study run by the peptide's own inventors, never independently replicated in the West.
As of July 2026, Epitalon (also spelled Epithalon) is legally unscheduled but not FDA-approved for human use in the US, EU, or any other major Western market — it's sold as a "research chemical" and used off-label through compounding pharmacies and longevity/biohacking circles. For the first time in its nearly 50-year life, it's back before American regulators: the FDA's Pharmacy Compounding Advisory Committee is scheduled to review it on July 23–24, 2026 to decide whether it belongs on the 503A compounding bulk-substances list. In Russia, related pineal preparations (Epithalamin) have a much longer run as licensed clinical products, though the underlying evidence remains almost entirely home-grown from Khavinson's institute and its close collaborators.
